Your browser version may not work well with NCBI's Web applications. More information here...
1: J Clin Psychopharmacol. 1988 Dec;8(6):391-6.Links
Erratum in:
J Clin Psychopharmacol 1989 Feb;9(1):3.

A trial of isocarboxazid in the treatment of bulimia nervosa.

Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE.

Department of Psychiatry, University of Toronto, Ontario, Canada.

Eighteen women completed a double-blind, placebo-controlled crossover study designed to investigate the effects of isocarboxazid in the treatment of bulimia nervosa. There was a significant reduction in binge eating and vomiting during isocarboxazid treatment. Response was not influenced by either the presence or absence of current major depression or personality disorder. There were no serious adverse effects from this monoamine oxidase inhibitor therapy, although over 50% of patients elected to discontinue isocarboxazid 1 year after the study.

PMID: 3069879 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Isocarboxazid (Marplan® )

    Isocarboxazid is used to treat depression in people who have not been helped by other antidepressants. Isocarboxazid is in a class of medications called monoamine oxidase inhibitors (MAOIs). It works by increasing the am...

  • Source: AHFS Consumer Medication Information